Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciSparc Ltd. ( (SPRC) ) has shared an update.
On February 2, 2026, SciSparc Ltd. reported that its approximately 75%-owned subsidiary NeuroThera Labs Inc. has been granted a new U.S. patent covering proprietary combinations of established antibiotics with cannabinoids such as THC, CBD and related compounds to enhance antimicrobial activity against resistant bacteria, including MRSA. The patent, which complements existing protections in the U.S. and Europe, underpins NeuroThera’s antimicrobial-potentiating platform that has shown in preclinical studies an “antimicrobial-sparing” effect that may restore the effectiveness of older antibiotics and reduce side effects and resistance pressure, potentially positioning SciSparc and NeuroThera as notable innovators in the large and increasingly challenged global antibiotics market, where traditional big pharma investment has waned despite rising mortality from antimicrobial resistance.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company that, through its majority-owned subsidiary NeuroThera Labs Inc., focuses on developing cannabinoid-based therapeutics. Its pipeline includes THC- and CBD-based drug candidates such as SCI-110 for Tourette syndrome and Alzheimer’s-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus, while it also holds a controlling interest in a business selling hemp seed oil-based products on Amazon.
Average Trading Volume: 2,086,268
Technical Sentiment Signal: Sell
Current Market Cap: $3.35M
Find detailed analytics on SPRC stock on TipRanks’ Stock Analysis page.